Insmed Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INSM research report →
Range $154 – $235
Price Chart
About the company
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils.
- CEO
- William H. Lewis
- IPO
- 2000
- Employees
- 1,664
- HQ
- Bridgewater, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is in a powerful multi-month uptrend and remains above its 200-day moving average, with price action pressing toward the upper end of its 52-week range. That keeps the regime constructive, though the move has become extended after a sharp re-rating from the lower half of the annual range.
Street sentiment stays constructive: the consensus is Buy, with a 191.06 average target versus a 143.89 share price. Recent calls mostly trimmed targets rather than changed ratings, and the pattern still shows repeated Buy reiterations alongside only one downgrade to Peer Perform.
The next report follows a mixed beat pattern, with Insmed beating EPS in 2 of the last 8 quarters. Estimates point to a sharp improvement, with 2027 EPS seen at 0.68236 versus TTM EPS of -2.81, so shareholders should watch whether revenue growth and margin progress keep narrowing losses.
Recent insider activity leans negative on the surface because the only clear discretionary trade was a 25,000-share sale by a director. The other entries are award-related or zero-share administrative filings, so they carry little signal beyond routine equity compensation.
Profitability remains weak, but the operating profile is improving from a growth base. Gross margin is 84.4%, while revenue growth is 2.684% year over year; the tradeoff is still heavy losses, with operating margin at -41.66% and free cash flow at -902.5 million for 2025.
Insmed stands out for premium gross margins and a strong pipeline, but it still trails profitable peers on earnings quality and cash generation. The valuation remains rich for a biotech with negative earnings, even after the recent reset in analyst targets.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.00B
- P/E
- -50.48
- Fwd P/E
- 207.12
- PEG
- -0.63
- P/S
- 20.55
- P/B
- 42.89
- EV/EBITDA
- -63.92
- Div Yield
- 0.00%
- Gross Margin
- 84.26%
- Op Margin
- -35.59%
- Net Margin
- -39.85%
- ROE
- -82.75%
- ROIC
- -32.75%
Latest fiscal year · YoY change
- Revenue
- $606.42M+66.7%
- Gross Profit
- $481.55M+73.2%
- Op Income
- $-1,176,729,000
- Net Income
- $-1,276,775,000-39.7%
- EPS
- $-6.41-15.1%
- OCF Growth
- -36.7%
- FCF Growth
- -37.1%
- 52W High
- $212.75
- 52W Low
- $90.39
- 50D MA
- $110.86
- 200D MA
- $122.61
- Beta
- 0.81
- RSI (14)
- 77
- Avg Volume
- 3.01M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Insmed posted a blockbuster BRINSUPRI quarter, raised full-year guidance for both BRINSUPRI and ARIKAYCE, and said its commercial momentum plus pipeline progress support a path to cash flow positivity in 2027.· October 29, 2026
- BRINSUPRI generated $400.1 million in Q3 2026 revenue, up 29% sequentially, and the company said it has already surpassed $1 billion in revenue in its first four full quarters of launch.
- ARIKAYCE revenue was $124.4 million in Q3 2026, up 9% year over year, and full-year guidance was raised on continued franchise strength.
- Insmed raised full-year 2026 revenue guidance to $1.35 billion-$1.4 billion for BRINSUPRI and $460 million-$470 million for ARIKAYCE.
- Management highlighted strong launch metrics for BRINSUPRI, especially payer approvals, reauthorizations, persistency, and dispenses, but stopped giving detailed launch metrics after the first year.
- The company said its pipeline remains active, with TPIP enrollment ahead of expectations, INS1033 and INS1148 moving toward phase II, and gene therapy data expected in 2027.
Q3 2026 revenue figures stated on the call included BRINSUPRI at $400.1 million, up 29% sequentially from the prior quarter, and ARIKAYCE at $124.4 million, up 9% year over year versus Q3 2025. Cost of product revenues was $78.2 million, or 14.9% of revenues, versus 20.6% in the prior-year quarter. Combined R&D and SG&A expenses increased 40% year over year, reflecting launch and pipeline investment. Cash equivalents and marketable securities were approximately $1.1 billion at quarter-end. Full-year 2026 guidance was raised to $1.35 billion-$1.4 billion for BRINSUPRI and $460 million-$470 million for ARIKAYCE; gross-to-net guidance was reiterated at mid-to-high 20s for BRINSUPRI and low-to-mid-20s for ARIKAYCE. Management said these revenue trends provide a clear line of sight to cash flow positivity in 2027.
Will Lewis framed the quarter as evidence that Insmed has become a diversified biotech with multiple blockbuster opportunities, led by BRINSUPRI, TPIP, and ARIKAYCE. His tone was highly upbeat and expansive, emphasizing that the company has only begun to penetrate the bronchiectasis market and that additional growth could come from broader prescribing, comorbid COPD/asthma patients, and international launches. He also underscored that the company is continuing to invest in commercial execution, real-world evidence, diagnostics, and business development while maintaining a long-term growth narrative.
Sara Bonstein focused on the strong revenue base, margin improvement, and balance sheet strength. She highlighted BRINSUPRI at $400.1 million and ARIKAYCE at $124.4 million, reiterated gross-to-net ranges, and noted that cost of product revenues was 14.9% of revenue versus 20.6% a year ago, which she tied to BRINSUPRI's favorable margin contribution. She said cash and marketable securities were approximately $1.1 billion and that the company has a clear line of sight to cash flow positivity in 2027, while also noting that TPIP spending has already included significant manufacturing investment that will shift toward clinical trial spend.
Analysts pressed on BRINSUPRI discontinuations, seasonality, prescriber breadth versus depth, DTC advertising, the comorbid COPD/asthma opportunity, and whether the patient pool is larger than expected. Management said discontinuation trends are 'doing better than expected,' seasonality is too early to call, and persistency is a key strength. On comorbid disease, Will Lewis argued the opportunity is large based on published literature and KOL feedback, said AI and workflow changes could improve diagnosis, and stated approval rates remain high with no expected reimbursement friction. He also said DTC marketing should start helping in the first half of next year and estimated the ILD TPIP study is about six months ahead of schedule.
The call showed strong commercial traction for BRINSUPRI, with management describing persistency, payer access, and patient-reported benefit as better than expected. Insmed also raised guidance, launched BRINSUPRI in Japan, advanced TPIP enrollment, and reiterated a path to cash flow positivity in 2027, all while signaling multiple future growth drivers beyond the current launch.
The company is making large ongoing investments in launch support, manufacturing, and multiple pipeline programs, which keeps expenses elevated. Management also acknowledged that the comorbid COPD/asthma opportunity will take time to prove out, seasonality is unclear, and TPIP remains in early-stage development with long timelines before data and potential approval. The ARIKAYCE growth opportunity depends on successful label expansion in both the U.S. and Japan, which is not yet secured.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.5%
- Shares Outstanding
- 219.38M
- Float Shares
- 216.14M
of shares held by institutions
721 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for INSM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Jun 10, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 3, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 22, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Aug 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jul 7, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 16, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 9, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 21, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 28, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 6, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 21.08M | ▲ 1.14M |
| Blackrock, Inc. | 15.91M | ▲ 100.60K |
| Fmr LLC | 15.52M | ▼ 625.45K |
| Vanguard Portfolio Management LLC | 10.53M | ▲ 122.02K |
| Vanguard Capital Management LLC | 9.83M | ▲ 42.58K |
| Capital International Investors | 9.35M | ▲ 1.11M |
| Baker Bros. Advisors LP | 8.80M | ▲ 1.38M |
| Jpmorgan Chase & Co | 8.24M | ▼ 2.18M |
| Darwin Global Management, Ltd. | 6.43M | ▼ 10.37M |
| Ameriprise Financial Inc | 6.18M | ▲ 3.12M |
| State Street Corp | 6.16M | ▲ 110.24K |
| Orbis Allan Gray Ltd | 6.08M | ▲ 4.20M |
Held by 1,157 ETFs
Biggest fund positions in INSM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| May 11, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Oct 30, 26 | Kane Patrick Kevin | other | 0 |
| Jan 6, 26 | Kane Patrick Kevin | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INSM coverage
Recent articles, reports, and earnings notes.

Insmed (INSM): BRINSUPRI Launch Drives the Bull Case
Insmed is scaling quickly on the back of BRINSUPRI, with ARIKAYCE still contributing meaningful cash flow. The stock looks attractive for investors who can accept biotech execution risk, but valuation remains demanding.

Insmed Incorporated (INSM) spikes 20% on Sanofi deal buzz
Insmed Incorporated (INSM) spikes after reports that Sanofi is weighing a possible acquisition, driving heavy volume and a volatility halt. The move comes as strong revenue growth and raised guidance add support to the biotech’s valuation, even as profitability remains uneven.

Insmed Incorporated (INSM) jumps 18.4% on Sanofi takeover buzz
Insmed Incorporated (INSM) jumps after a Bloomberg report said Sanofi is weighing an acquisition and has spoken with advisers. The move came on heavy volume and reflects rising takeover speculation around the biotech’s commercial products and late-stage pipeline.
Want a deeper read on INSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Insmed: Maintaining Strong Buy On Commercial Execution And Takeover Interest
seekingalpha.com · Nov 20
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
benzinga.com · Nov 20
Insmed Stock Rises: What's Going On?
benzinga.com · Nov 20
9,137 Shares of Insmed, Inc. $INSM Acquired by Banco Santander S.A.
defenseworld.net · Nov 20
Head-To-Head Survey: Entera Bio (NASDAQ:ENTX) & Insmed (NASDAQ:INSM)
defenseworld.net · Nov 20
Insmed shares jump 18% as Sanofi weighs potential takeover
proactiveinvestors.com · Nov 19
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners.
barrons.com · Nov 19
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
marketbeat.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice